than1.5 SD from mean) or motor function (Movement-ABC <15th centile). Initial univariate analysis was followed by multivariate analyses adjusting for socioeconomic index, maternal BMI, gestation and birthweight z score.
RELATION OF DEMOGRAPHIC CHARACTERISTICS WITH BURNOUT, SECONDARY TRAUMATIC STRESS AND COMPASSION SATISFACTION IN NICU NURSES
Method: An online self-report survey of clinical registered nurses-midwives and clinical nurse specialists working in four Level 5-6 NICUs in NSW, Australia between February and May, 2016.
Results: 141 (35%) of 405 eligible nurses completed the study questionnaires. The following zero-order correlations were significant: years of NICU experience (more vs. less) with BO (r =.18, p <.05) and STS (r =.18, p <.05); level of education (lower vs. higher) with STS (r =.16, p <.10); and employment status (full-time vs. part-time) with CS (r =.23, p <.01). NICU nurses' age, partner status, number of dependent children and NICU position were not significantly correlated with BO, STS or CS. Demographic factors explained < 10% of the variability in BO, STS and CS.
Conclusions: Attention to the demographic characteristics that correlate with BO, STS and CS may help unit managers and educators identify and support psychologically vulnerable NICU nurses and, perhaps, improve the recruitment, absenteeism and retention of NICU nurses. Background: Women with a previous pregnancy affected by preeclampsia and small for gestational age (SGA) are at an increased risk in future pregnancies. Past trials evaluating low molecular weight heparin show conflicting results with high levels of heterogeneity across trials.
THE EPPI TRIAL -ENOXAPARIN FOR THE PREVENTION
Methods: An international multicentre open-label randomised controlled trial. Inclusion criteria were: ?6 + 0 and ?15 + 6 weeks gestation with fetal viability and singleton pregnancy confirmed, and most recent pregnancy complicated by (i) pre-eclampsia delivered ?35 + 6 weeks, (ii) SGA <10th customised birthweight centile (CBWC) delivered ?35 + 6 weeks, or (iii) SGA?3rd CBWC delivered at any gestation. Women were randomly assigned to high risk care (HRC) plus enoxaparin 40 mg subcutaneously daily or HRC only. HRC included use of daily low dose aspirin. Randomisation was stratified according to inherited thrombophilia status. Serial serum samples were taken for assessment of placental and angiogenic markers. The primary outcome was the incidence of preeclampsia and/or SGA <5th CBWC. ACTRN12609000699268.
Results: 156 participants were enrolled, 149 participants were included in outcome analysis. Preeclampsia and/or SGA <5th CBWC occurred in 35 women (23.5%). Enoxaparin in addition to SHRC did not reduce the rate of preeclampsia and/or SGA <5th CBWC 18/72 (25.0%) enoxaprin group vs 17/77 (22.1%) (HRC only group) (OR 1.19, 95%CI 0.5-2.6) or of any secondary outcomes.
Conclusions: Enoxaparin in addition to high risk care does not reduce the risk of recurrence of preeclampsia and SGA infants in a subsequent pregnancy.
Results will be presented at SMFM, Las Vegas January 2017 We undertook a systematic review to evaluate the efficacy and safety of different intravenous (IV) iron preparations in the management of antenatal iron-deficiency anaemia (IDA).
Method: MEDLINE, Embase, and Scopus were searched to June 2016. Eligible studies were randomised controlled trials or observational studies, in any language, involving administration of IV iron (ferric carboxymaltose (FCM), iron polymaltose (IPM), or iron sucrose (IS)), regardless of comparator, to manage antenatal IDA. Data were extracted on study characteristics, maternal efficacy, treatment related adverse drug reactions (ADRs), and perinatal outcomes. Two independent reviewers selected studies, extracted data and assessed quality. Descriptive analyses were carried out.
